Cost-utility analysis of the treatment of relapsing-remitting multiple sclerosis with glatiramer acetate or interferon beta in Spain

被引：0
|
作者：
Rubio-Terrés, C
Medina, F
Aristegui, I
Izquierdo, G
机构：
[1] Aventis Pharma SA, Madrid, Spain
[2] Hosp Univ Virgen Macarena, Seville, Spain
来源：
VALUE IN HEALTH | 2003年 / 6卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)64043-0
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：277 / 277
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF GLATIRAMER ACETATE AND INTERFERON BETA-1A FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS, BASED ON THE COMBIRX STUDY
    Darba, J.
    Kaskens, L.
    Sanchez-de la Rosa, R.
    VALUE IN HEALTH, 2013, 16 (07) : A623 - A623
  • [22] Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study
    Rainel Sánchez-de la Rosa
    Laura García-Bujalance
    José Meca-Lallana
    Health Economics Review, 5
  • [23] Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients
    Romeo, M.
    Martinelli-Boneschi, F.
    Rodegher, M.
    Esposito, F.
    Martinelli, V.
    Comi, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2013, 20 (07) : 1060 - 1067
  • [24] Demographic and clinical predictors of response to interferon beta and glatiramer acetate as first-line treatment for relapsing-remitting multiple sclerosis
    Gajofatto, A.
    Bacchetti, E.
    Grimes, B.
    High, A.
    Moraes, C.
    Waubant, E.
    MULTIPLE SCLEROSIS, 2007, 13 : S57 - S58
  • [25] Cost-utility of interferon β1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis
    G. Kobelt
    L. Jönsson
    S. Fredrikson
    The European Journal of Health Economics, 2003, 4 (1) : 50 - 59
  • [26] Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States
    Hernandez, Luis
    Guo, Shien
    Kinter, Elizabeth
    Fay, Monica
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (07) : 684 - 695
  • [27] Glatiramer acetate - A review of its use in relapsing-remitting multiple sclerosis
    Simpson, D
    Noble, S
    Perry, C
    CNS DRUGS, 2002, 16 (12) : 825 - 850
  • [28] Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis
    Khan, Omar
    Rieckmann, Peter
    Boyko, Alexey
    Selmaj, Krzysztof
    Zivadinov, Robert
    ANNALS OF NEUROLOGY, 2013, 73 (06) : 705 - 713
  • [29] Glatiramer acetate (Copaxone) treatment in relapsing-remitting multiple sclerosis: Quantitative MR assessment
    Ge, Y
    Grossman, RI
    Udupa, JK
    Fulton, JC
    Babb, JS
    Constantinescu, CS
    RADIOLOGY, 1999, 213P : 441 - 441
  • [30] Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran
    Imani, Ali
    Golestani, Mina
    IRANIAN JOURNAL OF NEUROLOGY, 2012, 11 (03) : 87 - 90
12345